Clinical trials: Sitagliptin, completed
Obesity
Effect of DPP4 Inhibition on Growth Hormone Secretion
This study tests the following hypotheses: Aim 1: Test the hypothesis that acute dipeptidyl peptidase 4 (DPP4) inhibition with the currently available anti-diabetic drug, sitagliptin, will increase stimulated growth hormone (GH)…
- Trial name
- NCT01701973
- Testing
- Sitagliptin, Pegvisomant, L-NMMA
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University
Diabetes Mellitus, Non-Insulin-Dependent
A Study of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy (0431-054)(COMPLETED)
The clinical study determines the safety and efficacy of Sitagliptin (MK0431) in patients with type 2 diabetes mellitus who have inadequate glycemic control on diet/exercise therapy.
- Trial name
- NCT00411554
- Testing
- sitagliptin phosphate, Comparator: voglibose
- Volunteers
- 319 people
- Sponsor
- Merck Sharp & Dohme LLC
Healthy, Pharmacokinetics of ASP1941
A Study to Characterize the Effect on the Pharmacokinetics of ASP1941 and Sitagliptin When Given Together to Healthy Subjects
The purpose of the study is to evaluate pharmacokinetics, pharmacodynamics and safety following the administration of ASP1941 and sitagliptin in single and multiple doses.
- Trial name
- NCT01104532
- Testing
- ASP1941, sitagliptin
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Inc
Pharmacological Action
Sitagliptin and the Risk for Hypoglycaemia in Type 2 Diabetes Patients
Sitagliptin, through its effects on sensitizing alpha-cell sensitivity to glucose, can initiate counter-regulatory glucagon responses at higher glycemic thresholds, thus reducing the number of clinically apparent hypoglycemic…
- Trial name
- NCT03359590
- Testing
- Sitagliptin 100 mg
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Profil Institut für Stoffwechselforschung GmbH
Healthy Subjects
Bioequivalence of Sitagliptin Phosphate/Metformin Hydrochloride Tablets in Healthy Chinese Subjects
An open-label, randomized, single-dose, two-period, two-group, crossover study was conducted in 48 healthy Chinese volunteers under fasted or fed conditions (24 volunteers for each condition) to assess the bioequivalence between…
- Trial name
- NCT04877106
- Testing
- Sitagliptin Phosphate/metformin Hydrochloride Tablets(JANUMET®,50mg/850mg), Sitagliptin Phosphate/metformin Hydrochloride Tablets (50mg/850mg)
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- The Affiliated Hospital of Qingdao University
Type 2 Diabetes
Efficay and Safety of Empagliflozin Versus Sitagliptin for the In-patient Management of Hyperglycemia
Clinical guidelines from professional organizations have recommended the use of multidose insulin regimens as the preferred therapy for glycaemic control in patients admitted to hospital in a non-intensive-careunit setting.
- Trial name
- NCT06187285
- Testing
- Empagliflozin 25 MG, Sitagliptin 100mg
- Where
- India
- Volunteers
- 220 people
- Sponsor
- Medanta, The Medicity, India
Diabetes Mellitus, Type 2
The Effect of Linagliptin (BI 1356) on 24h-glucose Control and Various Biomarkers in Type 2 Diabetic Patients
The objective of this study is to investigate the effect of BI 1356 on 24-h glucose control and various pharmacodynamic parameters in type 2 diabetic patients with inadequate glycaemic control.
- Trial name
- NCT00716092
- Testing
- Sitagliptin, Linagliptin
- Where
- 3 sites in Germany
- Volunteers
- 121 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)
This study will compare the effects of 2.0 mg exenatide once weekly injection as monotherapy to 3 active comparators(metformin, dipeptidyl peptidase-4 inhibitor, and thiazolidinedione) in drug naive patients with type 2 diabetes…
- Trial name
- NCT00676338
- Testing
- exenatide once weekly, metformin, sitagliptin
- Where
- 106 sites in United States, Argentina and 20 more
- Volunteers
- 820 people
- Sponsor
- AstraZeneca
Uncontrolled Type 2 Diabetes Mellitus
Effect of CPL-2009-0031 in the Treatment of Patients With Uncontrolled Type 2 Diabetes Mellitus
This trial is a Phase-III, Prospective, Randomized, Double Blind, Parallel Group, Two arm, Comparative, Multicenter, controlled clinical trial to determine the efficacy, safety, and tolerability of oral CPL-2009-0031 140 mg in…
- Trial name
- NCT04801199
- Testing
- CPL-2009-0031 140 mg, Sitagliptin 100mg
- Where
- 12 sites in India
- Volunteers
- 355 people
- Sponsor
- Cadila Pharnmaceuticals
Acute Myocardial Infarction
Sitagliptin Plus Granulocyte-colony Stimulating Factor in Acute Myocardial Infarction
Trial design: This Phase III, investigator-driven, randomised, placebo-controlled efficacy and safety study will compare the effects of Sitagliptin in combination with granulocyte-colony stimulating factor (Lenograstim, G-CSF) on…
- Trial name
- SITAGRAMI (NCT00650143)
- Testing
- Lenograstim (GRANOCYTE)=GCSF, Sitagliptin (Januvia), Sodium Chloride (NaCl) 0.9 %
- Where
- Germany
- Volunteers
- 174 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Diabetes Mellitus, Type 2
Incretin-based Drugs and Acute Pancreatitis
The purpose of this study is to determine whether incretin-based drugs (used to treat type 2 diabetes) taken either alone or in combination with other anti-diabetic drugs are associated with an increased risk of acute…
- Trial name
- NCT02476760
- Testing
- DPP-4 inhibitors, GLP-1 analogs, Insulins
- Where
- Canada
- Volunteers
- 1,417,914 people
- Sponsor
- Canadian Network for Observational Drug Effect Studies, CNODES
Type 2 Diabetes
A Study Comparing the Safety, Tolerance, and Efficacy of Various Doses of SK-0403 Versus Placebo and Sitagliptin 100 mg in Patients Not Well-Controlled on Metformin Therapy
The purpose of this study is to evaluate the safety and efficacy of a range of doses of SK-0403 in subjects with type 2 diabetes that are not adequately controlled on metformin alone.
- Trial name
- NCT01169090
- Testing
- SK-0403, Sitagliptin
- Where
- 40 sites in United States
- Volunteers
- 620 people
- Sponsor
- Kowa Research Institute, Inc.
Diabetes, Diabetes Mellitus, Type 2
Effect of Detemir and Sitagliptin on Blood Glucose Control in Type 2 Diabetes
This trial is conducted in Asia, Europe and North America. This trial aims for comparison of the effect on the glycemic control in subjects with type 2 diabetes of basal insulin analogue with one oral anti-diabetic drug (OAD)…
- Trial name
- NCT00789191
- Testing
- insulin detemir, sitagliptin, metformin
- Where
- 51 sites in United States, Canada and 6 more
- Volunteers
- 222 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
Emulation of the REWIND Cardiovascular Outcomes Trial in Healthcare Claims Data.
Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials.
- Trial name
- NCT07417631
- Testing
- Dulaglutide, Sitagliptin
- Where
- United States
- Volunteers
- 300,000 people
- Sponsor
- Brigham and Women's Hospital
Type 2 Diabetes
SITAgliptin Plus GLARgine to Glycemic Control in the Hospital Setting (SITAGLAR-H)
In noncritically hospitalized patients, hyperglycemia (defined as blood glucose [BG] levels >140 mg/dL) is a common, serious, and costly healthcare problem.
- Trial name
- SITAGLAR-H (NCT05579119)
- Testing
- Sitagliptin 100mg, Glargine, Lispro
- Where
- Mexico
- Volunteers
- 76 people
- Sponsor
- Hospital de Especialidades, Centro Medico Nacional "La Raza", Instituto Mexicano del Seguro Social
Diabetes Mellitus, Type 2
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (Explores What the Body Does to the Drug), and Pharmacodynamics (Explores What a Drug Does to the Body) of JNJ-38431055 in Volunteers With Type 2 Diabetes Mellitus
This study will assess the safety, tolerability, pharmacokinetics (explores what the body does to the drug), and pharmacodynamics (explores what a drug does to the body) of JNJ-38431055 in volunteers with type 2 diabetes mellitus.
- Trial name
- NCT00871507
- Testing
- JNJ-38431055 Dose 1, Sitagliptin 100 mg, JNJ-38431055 Dose 2
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Type 2 Diabetes Mellitus
Phase 2 Study To Evaluate Safety And Efficacy Of Investigational Drug - PF04937319 In Patients With Type 2 Diabetes
B1621007 is designed to study the safety and efficacy of PF-04937319 in patients with type 2 diabetes
- Trial name
- NCT01475461
- Testing
- PF-04937319 - 3mg, PF-04937319 - 20mg, PF-04937319 - 50mg
- Where
- 63 sites in United States, Hungary and 6 more
- Volunteers
- 345 people
- Sponsor
- Pfizer
Type 2 Diabetes Mellitus, Hypertension
Effect of Chronic ACE and DPP4 Inhibition on Blood Pressure
In this study the investigators will test the hypothesis that dipeptidyl peptidase IV (DPP4) inhibition attenuates the antihypertensive effect of angiotensin-converting enzyme (ACE) inhibition but not angiotensin receptor…
- Trial name
- NCT02130687
- Testing
- Sitagliptin, Aprepitant, Mixed Meal Test (MMT)
- Where
- United States
- Volunteers
- 106 people
- Sponsor
- Vanderbilt University
Type 2 Diabetes Mellitus
A Study to Investigate the Glucose Lowering Effects of Dextromethorphan Alone or in Combination With Sitagliptin in Subjects With Type 2 Diabetes Mellitus (T2DM) After an Oral Glucose Tolerance Test
The study has a randomized, double-blind, placebo-controlled, double dummy and eight-way cross-over design. Males with T2DM on a stable metformin monotherapy will be screened for participation in the study.
- Trial name
- DXM2 (NCT01936025)
- Testing
- Dextromethorphan, Sitagliptin
- Where
- Germany
- Volunteers
- 34 people
- Sponsor
- Profil Institut für Stoffwechselforschung GmbH
Diabetes Mellitus
Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus
The purpose of this study is to determine the efficacy and safety of SYR-472, once daily (QD), in subjects with type 2 diabetes mellitus who have not achieved glycemic control with diet and exercise, or by taking metformin.
- Trial name
- NCT00760344
- Testing
- SYR-472, Sitagliptin
- Where
- 112 sites in United States, Mexico
- Volunteers
- 386 people
- Sponsor
- Takeda